Merck Sharp + Dohme Corp.

Anthony T Ginnetti

Daniel Vincent Paone

Ian M Bell

Mark E Fraley

Cheng Wang

Helen J Mitchell

Steven N Gallicchio

Donnette D Staas

Shawn J Stachel

Christopher S Burgey

C Blair Zartman

Michael J Breslin

Heather E Stevenson

Ashok Arasappan

Jian Liu

James J Perkins

Jason M Cox

Mark E Layton

Hong Liu

Harry R Chobanian

Jianmin Fu

Christopher James Bungard

Shimin Xu

Jing Li

Deodial Guy Guiadeen

Kristen L G Jones

Zhe Wu

Linda M Suen-Lai

Stephane L Bogen

Craig A Stump

Anthony W Shaw

Michael T Rudd

Dane James Clausen

Zhengwu James Deng

Diem N Nguyen

Dexi Yang

John Jin Lim

Ashley Nomland

Blair C Zartman

John Lim

Zhengwu J Deng

The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Pyrrolidine orexin receptor agonists

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. 

2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide azaindane CGRP receptor antagonists

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide indane CGRP receptor antagonists

The present invention is directed to fused heterocyclic azaindane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Fused heterocyclic azaindane carboxamide CGRP receptor antagonists

The present invention is directed to fused heterocyclic indane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Fused heterocyclic indane carboxamide CGRP receptor antagonists

The subject invention relates to novel P2Xreceptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2Xreceptor subunit modulator.

P2X3, receptor antagonists for treatment of pain

Growing community of inventors

Perkasie, PA, United States of America

Anthony T Ginnetti